# Chemical Compounds for Treating Hepatitis C Virus

> A patent describing specific chemical structures designed to stop the Hepatitis C virus from replicating in humans.

- **Patent:** US 8822430
- **Original title:** Antiviral compounds
- **Owner:** Gilead Pharmasset LLC
- **Granted:** 2014
- **Status:** Active
- **Times cited:** 11
- **Field:** pharmaceutical, biotech

## What it does

This patent defines a series of chemical structures, specifically compounds containing benzimidazolyl and heteroaryl rings, that act as antiviral agents. These molecules are engineered to interfere with the life cycle of the Hepatitis C virus (HCV). By administering these compounds, as described in claims 16 and 17, the patent outlines a method to inhibit the virus's ability to multiply within a human patient. The patent also covers the pharmaceutical compositions, meaning the specific mixtures of these chemicals with carriers that allow them to be safely delivered as medicine.

## What it does NOT cover

- Does not cover general antiviral treatments for viruses other than Hepatitis C.
- Does not cover natural, non-synthetic chemical compounds found in nature.
- Does not cover methods of treating HCV using different chemical scaffolds not defined by the specific formulas in the claims.
- Does not cover medical devices or diagnostic tools for detecting the virus.

## The clever bit

The innovation lies in the specific arrangement of the benzimidazolyl and heteroaryl groups, which allows the molecule to bind precisely to viral proteins, effectively shutting down the virus's replication machinery.

## Real-world examples

1. Direct-acting antiviral medications for Hepatitis C
2. Pharmaceutical formulations for oral HCV therapy

## Why it matters

This patent is part of the intellectual property portfolio that enabled the development of highly effective direct-acting antivirals for Hepatitis C. These drugs transformed HCV from a chronic, often fatal condition into a curable disease. It represents a significant milestone in medicinal chemistry and public health.

## Frequently asked questions

### What does Chemical Compounds for Treating Hepatitis C Virus cover?

A patent describing specific chemical structures designed to stop the Hepatitis C virus from replicating in humans.

### Who owns patent US 8822430?

Gilead Pharmasset LLC owns this patent, granted in 2014.

### When does this patent expire?

This patent is expected to expire on September 2, 2034, when the invention enters the public domain.

### What is patent US 8822430 cited by?

This patent has been cited by 11 later patents that build on its ideas.

### What problem does this patent solve?

This patent is part of the intellectual property portfolio that enabled the development of highly effective direct-acting antivirals for Hepatitis C. These drugs transformed HCV from a chronic, often fatal condition into a curable disease. It represents a significant milestone in medicinal chemistry and public health.

### What does this patent NOT cover?

Does not cover general antiviral treatments for viruses other than Hepatitis C.

**Full plain-English explainer:** https://patentbrief.org/patent/us/8822430/epclusa-sofosbuvir-velpatasvir

**Original patent:** https://patents.google.com/patent/US8822430

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._


## Related patents

Semantically similar inventions in the PatentBrief corpus:

- [Gilead's Chemical Compounds for Treating HIV Infections](https://patentbrief.org/patent/us/9216996/genvoya-elvitegravir-cobicistat-taf-ftc) — This patent covers specific chemical structures designed to block HIV from replicating in human cells, providing a foundation for new antiviral medications.
- [How Gilead Made a Stable HIV Pill Combining Two Medicines](https://patentbrief.org/patent/us/8592397/truvada-tdf-ftc-for-prep) — This patent describes a stable, single-pill combination of two HIV drugs, tenofovir disoproxil fumarate and emtricitabine, designed to prevent them from breaking down when stored together.
- [New Chemical Compounds for Protecting Crops from Fungal Diseases](https://patentbrief.org/patent/us/10626109/symdeko-tezacaftor-ivacaftor) — A patent describing a specific family of chemical compounds designed to kill or inhibit the growth of fungi that damage agricultural crops.
- [How a Cholesterol-Lowering Drug Molecule Was Patented](https://patentbrief.org/patent/us/5273995/viagra-sildenafil) — This patent protects the specific chemical structure of a molecule designed to lower cholesterol, including its various salt forms and its use in medicine.
- [How Ibrutinib-like Molecules Block Cancer-Causing Proteins](https://patentbrief.org/patent/us/8957079/pomalyst-pomalidomide) — A chemical design for molecules that permanently latch onto and disable a specific protein called Btk, which is often responsible for the growth of certain blood cancers.